Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease

Chinese Medical Journal

Volumn 123, Issue 15, 2010, Pages 2012-2017

  Peng, Sui ^a   Xiong, Li Shou ^a   Xiao, Ying Lian ^a   Wang, An Jiang ^a   Lin, Jin Kun ^a   Hu, Pin Jin ^a   Chen, Min Hu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Esomeprazole; Esophageal pH level; Gastroesophageal reflux; Symptom response

Indexed keywords

ESOMEPRAZOLE;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HIATUS HERNIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PH MEASUREMENT; PROSPECTIVE STUDY; REFLUX ESOPHAGITIS; SYMPTOM;

ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL PH MONITORING; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77956127172     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.15.011     Document Type: Article

References (22)

1. Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008; 23: 8-22.
2. Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 2004; 64: 277-295.
3. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003; 98 (3 Suppl): S31-S39.
4. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 15; 20: 637-643.
5. Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of oesophageal and gastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 2004; 99: 991-996.
6. Cheung TK, Wong WM, Wong NY, Chan CK, Fung J, Yuen MF, et al. Symptom resolution does not predict healing of erosive oesophagitis in Chinese. Digestion 2007; 75: 128-134.
7. Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007; 25: 617-628.
8. Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99: 981-988.
9. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, et al. The endoscopic assessment of oesophagits: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
10. Inamori M, Togawa J, Nagase H, Abe Y, Umezawa T, Nakajima A, et al. Clinical characteristics of Japanese reflux esophagitis patients as determined by Los Angeles classification. J Gastroenterol Hepatol 2003; 18: 172-176.
11. Peng S, Cui Y, Xiao YL, Xiong LS, Hu PJ, Li CJ, et al. Prevalence of erosive esophagitis and Barrett's esophagus in the adult Chinese population. Endoscopy 2009; 41: 1011-1017.
12. Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background processes, terminology, recommendations, and discussion outputs. Gut 2004; 53 Suppl 4: iv1-iv24.
13. Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005; 21: 455-463.
14. Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006; 51: 844-850.
15. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-979.
16. Körner T, Schütze K, van Leendert RJ, Fumagalli I, Costa Neves B, Bohuschke M, et al. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion 2003; 67: 6-13.
17. Kahrilas PJ, Quigley EM. American Gastroenterological Association Medical Position Statement: guidelines on the use of esophageal pH recording. Gastroenterology 1996; 110: 1982-1996.
18. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398-1402.
19. Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 2001; 281: G743-G751.
20. Fass R, Murthy U, Hayden CW, Malagon IB, Pulliam G, Wendel C, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14: 1595-1603.
21. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Gastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20: 399-406.
22. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-1356.